FDA Grants Orphan Drug Designation to Celularity’s CYNK-101, an NK Cell Therapy for GI Cancers

FLORHAM PARK, N.J., Feb. 15, 2022 — Celularity Inc. (Nasdaq: CELU), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational natural killer (NK) cell therapy, CYNK-101, for treatment of gastric/gastroesophageal junction cancer.

Treefrog Therapeutics appoints Scientific Advisory Board to guide the development of proprietary iPS platform & cell therapy pipeline

Bordeaux, France / March 1st, 2022 – TreeFrog Therapeutics, a French-based biotech aimed at making safer, more efficient and more affordable off-the-shelf cell therapies based on induced pluripotent stem cells (iPSCs), announces the formation of its Scientific Advisory Board (SAB). Bringing together world-class experts in biophysics, pluripotent stem cell biology and gene editing, the newly created SAB will guide the development of proprietary C-StemTM technology platform and in-house cell therapy programs.

Ciloa secures €5 million for the development of its new generation of biomedicines and vaccines using exosomes

Montpellier, France, March 08th 2022 – Ciloa, a pioneer company expert in the in vivo customization of exosomes, announced that it has secured €5 million to pursue its development programs for exosome-based biomedicines and vaccines. These funds will be used notably for the development of a new generation of natural vaccines using exosomes to prevent SARS-CoV-2 infection, including the variants responsible for the severe form of Covid-19.

GIOSTAR Chicago Explores Holistic Healing with Chopra Global Chief Medical Officer

CHICAGO, Feb. 22, 2022 — GIOSTAR Chicago – a leader in regenerative technologies – recently conducted a discussion on holistic healing with Dr. Sheila Patel. The conversation was led by Shelly Sood, GIOSTAR Chicago Founding Partner. Dr. Patel is a board-certified family physician and Chief Medical Officer (CMO) of Chopra Global – “a modern healthcare company positioned at the intersection of science and spirituality,” founded by renowned healthcare expert Dr. Deepak Chopra. The full interview is available on the GIOSTAR Chicago Website, with an accompanying transcript.

Ageless Biotech Announces FDA Accepted Phase IIb Study Targeting Moderate to Severe Osteoarthritis of the Knee Joint

February 18, 2022, Sheridan, WY — Ageless Biotech, Inc., a biotech company created to bring stem cell-based therapeutics to market, has acquired a U.S. FDA Investigational New Drug Application (IND) for the treatment of Osteoarthritis of the Knee. The Ageless Biotech IND utilizes minimally manipulated Adipose Derived Stem Cells without enzymes or other chemicals through a proprietary process of a well-known method referred to as Stromal Vascular Fraction (SVF) which creates a matrix of live human cells.

EdiGene and Neukio to Develop iPSC-Derived NK Cell Therapies

Feb. 9, 2022, BEIJING & SHANGHAI & CAMBRIDGE, Mass. – EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer, and Neukio Biotherapeutics, a biotechnology company focused on the development and commercialization of allogenic iPSC-CAR-NK cell therapies, announced an R&D collaboration to develop next-generation immune cell therapies.

Legend Biotech's  CARVYKTI™ Becomes Latest CAR-T Therapy Approved by U.S. FDA

February 28, 2022, SOMERSET, N.J. — Legend Biotech Corporation (NASDAQ: LEGN) announced that the U.S. FDA has approved its first product, CARVYKTI™ (ciltacabtagene autoleucel), for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received four or more prior lines of therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. to develop and commercialize CARVYKTI™ in December 2017.

Exogenus Therapeutics and Boehringer Ingelheim Collaboratively Explore Extracellular Vesicles for Regenerative Medicine Applications

Cantanhede, Portugal, March 2, 2022 – Exogenus Therapeutics is proud to announce a new research collaboration with Boehringer Ingelheim to explore the use of extracellular vesicles as therapeutic tools for regenerative medicine. This joint effort led by Boehringer Ingelheim’s Research Beyond Borders (RBB) Unit focuses on pre-clinical testing of Exogenus Therapeutics’ lead candidate Exo-101, in various regenerative medicine indications.

Exosomes: Company Spotlights from “A” to “Z”

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.

Who’s Who in the Induced Pluripotent Stem Cell (iPSC) Market

Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector.

Global Database of CAR-T Cell Companies, 2022 (50% Off)

Since the first historic CAR-T approvals in 2017, Kymriah (tisagenlecleucel), Yescarta (axicabtagene ciloleucel), Tecartus (brexucabtagene autoleucel), Breyanzi (lisocabtagene maraleucel), Abecma (idecabtagene vicleucel), and Relma-cel (relmacabtagene autoleucel) have reached commercialization. To track the competitors who compose this rapidly expanding marketplace, BioInformant has released a global database of all known CAR-T cell therapy companies—currently 161 worldwide. 

For a limited-time, you can claim this database for an unusual 50% off.

To access other market insights about CAR-T cell therapy, MSCs, iPSCs, cord blood, and beyond, explore the BioInformant Shop.

*Want to advertise in this newsletter? Contact us at Info@BioInformant.com.